



Advancing Care in Multiple Myeloma: A New Clinical Research Study

A Study to Investigate the Efficacy, Safety and Tolerability of An Investigational Study Drug (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving BCMA×CD3–Directed Bispecific Antibody Therapy

About the MMyrelis Clinical Research Study

The MMyrelis clinical research study is a phase 3, unblinded study, evaluating whether an investigational study drug can help prevent infections in adults with Multiple Myeloma (MM) who are currently treated with teclistamab.

The investigational study drug is an IVIG (Immune Globulin Infusion (Human) 10%), replacement therapy that has been approved globally to treat autoimmune disorders, Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN).

Participants who agree to consent, enrol and undergo the screening process will be administered an infusion once every 3 or 4 weeks, depending on the dosing schedule chosen between the participant and the study doctor.

This study will take up to 14 months and may require the participant to attend roughly 18 study visits.

Eligible patients must:



**Be 18 years
old or older**



**Have been
diagnosed
with MM**



**Have recently
started or be about
to start treatment for
MM with teclistamab**



**Continue treating
their MM with
teclistamab for at
least 12 months**

Other criteria must also be met to participate.

Study-related procedures and drugs will be provided to qualified participants at no cost. This may include study-related travel expenses based on regional regulatory approvals.

For more information regarding the MMyrelis clinical research study, please visit clinicaltrials.gov, the study website [url], or reach out to me directly.

If you are interested in sharing information with a patient who you feel may be eligible, please share the study video using the QR Code below or the study website.



<https://mmyrelisstudy.com/en-au/hcpf>

Name of contact person at study site



Telephone:



Email:



Protocol Number: TAK-339-3001

© Takeda Development Center Americas, Inc. All rights reserved.

TAK-339-3001_HCP Flyer_Layout_V1.0_14Apr2025_AU_ENG

